Supplementary Table 5. Baseline Characteristics of Patients with a Confirmed Diagnosis of Crohn's Disease by Second Line Treatment

Characteristic	Adalimumab (n = 53)	Infliximab (n = 61)	Vedolizumab (n = 11)	Ustekinumab (n = 112)
Sex				
Male	39 (73.6)	42 (68.9)	10 (90.9)	87 (77.7)
Female	14 (26.4)	19 (31.1)	1 (9.1)	25 (22.3)
Age at commencement of second line (yr)				
Mean ± SD	33.6 ± 12.4	34.0 ± 12.9	41.6 ± 12.0	34.3 ± 13.0
Median (IQR)	31 (23–42)	29 (23–45)	46 (40–48)	32 (23–44)
Charlson Comorbidity Index				
Mean ± SD	1.13 ± 1.50	0.98 ± 1.40	0.64 ± 1.00	0.77 ± 1.00
Median (IQR)	1 (0–1)	1 (0–1)	0 (0–1)	1 (0–1)
0	23 (43.4)	27 (44.3)	7 (63.6)	55 (49.1)
1–2	22 (41.5)	28 (45.9)	3 (27.3)	50 (44.6)
3–5	6 (11.3)	5 (8.2)	1 (9.1)	6 (5.4)
> 5	2 (3.8)	1 (1.6)	0	1 (0.9)
Hospitalizations within 6 mo prior to second line				
Yes	10 (18.9)	30 (49.2)	3 (27.3)	21 (18.8)
No	43 (81.1)	31 (50.8)	8 (72.7)	91 (81.3)
Time from first- to second line (day)				
Mean ± SD	727.9 ± 785.3	595.3 ± 527.3	1,134.4 ± 949.1	908.8 ± 780.5
Median (IQR)	470 (269–875)	357 (215–911)	678 (371–1,977)	642 (294–1,349)

Values are presented as number (%) unless otherwise indicated.
SD, standard deviation; IQR, interquartile range.